<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492503</url>
  </required_header>
  <id_info>
    <org_study_id>CA CX CHEMOTHERAPY</org_study_id>
    <nct_id>NCT02492503</nct_id>
  </id_info>
  <brief_title>Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix</brief_title>
  <official_title>An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experience with substituting carboplatin for cisplatin is limited in advanced and recurrent
      cervix cancer and there has been no counterpart to GOG 158, which documented therapeutic
      equivalency of cisplatin/paclitaxel and carboplatin/paclitaxel for treatment of ovarian
      cancer, performed in a cervix cancer population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be a prospective, randomized phase II pilot study. Consecutive patients of
      metastatic, recurrent or refractory carcinoma cervix enrolled in gynecology clinic at IRCH,
      AIIMS will be taken into study after taking informed consent. Patients will be randomized
      into two arms. Each arm shall contain 20 patients. The patients shall receive paclitaxel and
      carboplatin q3wk in first arm and paclitaxel and carboplatin q1 wk in second arm.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (length of time from start of chemotherapy to evidence of cancer progression.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Of Life Questionnaire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Carcinoma to the Uterine Cervix</condition>
  <condition>Recurrent Carcinoma Cervix</condition>
  <condition>Cervix Carcinoma Recurrent</condition>
  <arm_group>
    <arm_group_label>pacli carb 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pacli carb 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and carboplatin</intervention_name>
    <description>Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly</description>
    <arm_group_label>pacli carb 1</arm_group_label>
    <other_name>Arm1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel and carboplatin</intervention_name>
    <description>Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly</description>
    <arm_group_label>pacli carb 3</arm_group_label>
    <other_name>Arm 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Histologically proven case of squamous or adenocarcinoma or adenosquamous carcinoma
        2.ECOG performance status 0,1 and 2 3.Adequate hematologic, renal and liver functions
        4.Informed consent 5.Measurable disease by CT scan or USG abdomen or MRI

        Exclusion Criteria:

          1. ECOG performance status 3 or 4

          2. Impaired blood counts: those patients with an absolute neutrophil count &lt;1,500/μL,
             platelet counts &lt;100,000/μL, will be ineligible.

          3. Impaired renal /liver functions as indicated by:

        Serum bilirubin &gt;1.5× normal, AST level more than 3× normal, Alkaline phosphatase level
        more than 3× institutional normal, or a Serum creatinine level more than 1.2 mg/dL.
        Patients with serum creatinine level of more than 1.2 mg/dL but less than 1.5 mg/dL are
        eligible if creatinine clearance is 70 ml/min were eligible if a creatinine clearance
        determination was more than 50 mL/min.

        4. H/o prior chemotherapy for metastatic disease, 5. H/O concurrent or past malignancy
        other than carcinoma cervix, 6. CNS metastasis, or 7. Bilateral hydronephrosis that could
        not be alleviated by ureteral stents or percutaneous nephrostomy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lalit kumar, MD,DM</last_name>
    <role>Study Chair</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIIMS</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731017/</url>
    <description>Witteveen PO et al</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>July 7, 2015</last_update_submitted>
  <last_update_submitted_qc>July 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Harish P</investigator_full_name>
    <investigator_title>senior resident</investigator_title>
  </responsible_party>
  <keyword>recurrent or metastatic carcinoma cervix chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

